209 related articles for article (PubMed ID: 24925606)
41. Patient outcomes in schizophrenia II: the impact of cognition.
Hofer A; Baumgartner S; Bodner T; Edlinger M; Hummer M; Kemmler G; Rettenbacher MA; Fleischhacker WW
Eur Psychiatry; 2005 Aug; 20(5-6):395-402. PubMed ID: 16171654
[TBL] [Abstract][Full Text] [Related]
42. Verbal working memory in schizophrenia: The role of syntax in facilitating serial recall.
Li AWY; Viñas-Guasch N; Hui CLM; Chang WC; Chan SKW; Lee EHM; Chen EYH
Schizophr Res; 2018 Feb; 192():294-299. PubMed ID: 28392209
[TBL] [Abstract][Full Text] [Related]
43. General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia.
Réthelyi JM; Czobor P; Polgár P; Mersich B; Bálint S; Jekkel E; Magyar K; Mészáros A; Fábián A; Bitter I
Eur Arch Psychiatry Clin Neurosci; 2012 Mar; 262(2):107-15. PubMed ID: 21792534
[TBL] [Abstract][Full Text] [Related]
44. Memory systems in schizophrenia: Modularity is preserved but deficits are generalized.
Haut KM; Karlsgodt KH; Bilder RM; Congdon E; Freimer NB; London ED; Sabb FW; Ventura J; Cannon TD
Schizophr Res; 2015 Oct; 168(1-2):223-30. PubMed ID: 26299707
[TBL] [Abstract][Full Text] [Related]
45. Cognitive and symptomatic predictors of functional disability in schizophrenia.
Shamsi S; Lau A; Lencz T; Burdick KE; DeRosse P; Brenner R; Lindenmayer JP; Malhotra AK
Schizophr Res; 2011 Mar; 126(1-3):257-64. PubMed ID: 20828991
[TBL] [Abstract][Full Text] [Related]
46. The effect of long-term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls--a randomized placebo-controlled, double-blind fMRI study.
Guse B; Falkai P; Gruber O; Whalley H; Gibson L; Hasan A; Obst K; Dechent P; McIntosh A; Suchan B; Wobrock T
Behav Brain Res; 2013 Jan; 237():300-7. PubMed ID: 23022750
[TBL] [Abstract][Full Text] [Related]
47. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
[TBL] [Abstract][Full Text] [Related]
48. Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia.
Reilly JL; Harris MS; Khine TT; Keshavan MS; Sweeney JA
Biol Psychiatry; 2007 Oct; 62(7):818-21. PubMed ID: 17300756
[TBL] [Abstract][Full Text] [Related]
49. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
[TBL] [Abstract][Full Text] [Related]
50. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up.
Tabarés-Seisdedos R; Balanzá-Martínez V; Sánchez-Moreno J; Martinez-Aran A; Salazar-Fraile J; Selva-Vera G; Rubio C; Mata I; Gómez-Beneyto M; Vieta E
J Affect Disord; 2008 Aug; 109(3):286-99. PubMed ID: 18289698
[TBL] [Abstract][Full Text] [Related]
51. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.
Meltzer HY; McGurk SR
Schizophr Bull; 1999; 25(2):233-55. PubMed ID: 10416729
[TBL] [Abstract][Full Text] [Related]
52. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
Bobes J; Arango C; Garcia-Garcia M; Rejas J;
J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
[TBL] [Abstract][Full Text] [Related]
53. Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia.
Hori H; Yoshimura R; Katsuki A; Atake K; Igata R; Konishi Y; Beppu H; Tominaga H
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272307
[TBL] [Abstract][Full Text] [Related]
54. Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.
Bishop JR; Reilly JL; Harris MS; Patel SR; Kittles R; Badner JA; Prasad KM; Nimgaonkar VL; Keshavan MS; Sweeney JA
Psychopharmacology (Berl); 2015 Jan; 232(1):145-54. PubMed ID: 25096017
[TBL] [Abstract][Full Text] [Related]
55. Attention/vigilance in schizophrenia: performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS).
Nuechterlein KH; Green MF; Calkins ME; Greenwood TA; Gur RE; Gur RC; Lazzeroni LC; Light GA; Radant AD; Seidman LJ; Siever LJ; Silverman JM; Sprock J; Stone WS; Sugar CA; Swerdlow NR; Tsuang DW; Tsuang MT; Turetsky BI; Braff DL
Schizophr Res; 2015 Apr; 163(1-3):38-46. PubMed ID: 25749017
[TBL] [Abstract][Full Text] [Related]
56. Triiodothyronine may be possibly associated with better cognitive function and less extrapyramidal symptoms in chronic schizophrenia.
Ichioka S; Terao T; Hoaki N; Matsushita T; Hoaki T
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):170-4. PubMed ID: 22750309
[TBL] [Abstract][Full Text] [Related]
57. Neurocognitive deficits or stress overload: Why do individuals with schizophrenia show poor performance in neurocognitive tests?
Krkovic K; Moritz S; Lincoln TM
Schizophr Res; 2017 May; 183():151-156. PubMed ID: 27838097
[TBL] [Abstract][Full Text] [Related]
58. Predictors of cognitive and functional improvement and normalization after cognitive remediation in patients with schizophrenia.
Vita A; Deste G; De Peri L; Barlati S; Poli R; Cesana BM; Sacchetti E
Schizophr Res; 2013 Oct; 150(1):51-7. PubMed ID: 23998953
[TBL] [Abstract][Full Text] [Related]
59. Characteristics and clinical correlates of prospective memory performance in first-episode schizophrenia.
Zhou FC; Xiang YT; Wang CY; Dickerson F; Au RW; Zhou JJ; Zhou Y; Shum DH; Chiu HF; Man D; Lee EH; Yu X; Chan RC; Ungvari GS
Schizophr Res; 2012 Mar; 135(1-3):34-9. PubMed ID: 22222379
[TBL] [Abstract][Full Text] [Related]
60. Subjective cognitive dysfunction associated with drug-induced parkinsonism in schizophrenia.
Kim JH; Kim SY; Byun HJ
Parkinsonism Relat Disord; 2008; 14(3):239-42. PubMed ID: 17851106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
